TRV GP III’s Revolution Medicines RVMD Stock Holding History

TRV GP III’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,604,130	Closed	-$38.2M	–	5
2022 Q4	$38.2M	Sell	1,604,130 -2,000,000	-55%	-$42.5M	29.95%	1
2022 Q3	$71.1M	Sell	3,604,130 -1,500,000	-29%	-$33M	31.03%	2
2022 Q2	$99.5M	Sell	5,104,130 -419,901	-8%	-$8.17M	40.69%	1
2022 Q1	$141M	Hold	5,524,031	–	–	38.24%	1
2021 Q4	$139M	Hold	5,524,031	–	–	34.79%	1
2021 Q3	$152M	Hold	5,524,031	–	–	28.85%	1
2021 Q2	$175M	Hold	5,524,031	–	–	30.61%	1
2021 Q1	$253M	Sell	5,524,031 -1,500,000	-21%	-$67.3M	32.06%	1
2020 Q4	$278M	Sell	7,024,031 -1,000,000	-12%	-$39.5M	23.88%	2
2020 Q3	$279M	Sell	8,024,031 -1,000,000	-11%	-$27.7M	23.46%	2
2020 Q2	$285M	Hold	9,024,031	–	–	41.58%	1
2020 Q1	$198M	Buy	+9,024,031	New	+$250M	53.79%	1

Other funds holding RVMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

TRV GP III's RVMD Position: Q1 2023 in Review

TRV GP III sold out of Revolution Medicines (RVMD) in Q1 2023, closing a stake of 1,604,130 shares — an estimated $38.2M sold.

TRV GP III first reported a position in RVMD in Q1 2020 and held it in 12 quarters. The position peaked at $285M in Q2 2020. 152 funds tracked by Wall St. Rank hold RVMD as of Q1 2023.

TRV GP III reported no remaining Revolution Medicines position as of Q1 2023 after selling out during the quarter.
TRV GP III sold 1,604,130 Revolution Medicines shares in Q1 2023, an estimated $38.2M.
TRV GP III first reported a position in Revolution Medicines in Q1 2020 and held it in 12 quarters.
TRV GP III's Revolution Medicines position peaked at $285M in Q2 2020.
152 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2023.

Based on TRV GP III's 13F filing for Q1 2023, filed 12 May 2023.